By Fineline Cube Gan & Lee Pharmaceuticals (SHA: 603087) announced that the Ministry of Health and Prevention (MOHAP) of the United Arab Emirates has granted marketing approval for its insulin glargine injection in prefilled pen formulation. The approval marks a significant milestone in Gan & Lee’s international expansion strategy and provides UAE patients with access to a long-acting basal insulin featuring stable 24-hour glucose control and a peak-free pharmacokinetic profile.
Regulatory Milestone
| Parameter | Detail |
|---|---|
| Regulatory Agency | MOHAP (United Arab Emirates) |
| Product | Insulin glargine injection (prefilled pen) |
| Indication | Basal insulin therapy for diabetes mellitus |
| Administration | Once-daily subcutaneous injection |
| Duration of Action | 24 hours |
| Formulation | Prefilled pen for patient convenience |
Product Profile & Clinical Advantages
- Pharmacokinetic Profile: Flat, peak-free plasma concentration providing consistent basal insulin coverage throughout the day
- Glucose Control: Stable blood glucose management with reduced risk of hypoglycemic episodes compared to intermediate-acting insulins
- Patient Convenience: Prefilled pen formulation enhances adherence and simplifies dose administration compared to vial-and-syringe delivery
- Dosing Flexibility: Once-daily administration can be given at any time of day, accommodating diverse patient lifestyles
Strategic Market Expansion
- UAE Diabetes Burden: United Arab Emirates faces one of the world’s highest diabetes prevalence rates at 19.3% among adults, creating substantial demand for effective insulin therapies
- GCC Market Gateway: UAE approval serves as strategic foothold for broader Gulf Cooperation Council (GCC) market expansion, including Saudi Arabia, Qatar, and Kuwait
- Global Insulin Market: Entry into the $20+ billion global insulin market, competing with established players like Sanofi (Lantus), Eli Lilly (Basaglar), and Novo Nordisk (Toujeo)
- Chinese Pharmaceutical Leadership: Demonstrates Chinese biopharmaceutical companies’ capability to meet stringent international regulatory standards for complex biologic products
Competitive Landscape & Commercial Outlook
The UAE approval positions Gan & Lee’s insulin glargine as a cost-effective alternative to originator and other biosimilar products in a market increasingly focused on healthcare affordability. The prefilled pen formulation addresses growing patient preference for convenient, user-friendly delivery systems in chronic disease management.
Industry analysts estimate the UAE insulin glargine market at $80–120 million annually, with potential for rapid market penetration given Gan & Lee’s competitive pricing strategy and established manufacturing quality systems. The approval also validates Gan & Lee’s broader international regulatory strategy, supporting ongoing filings in other emerging markets.
Forward-Looking Statements
This brief contains forward-looking statements regarding regulatory approvals, market opportunities, and commercial expectations. Actual results may differ due to market dynamics, competitive pressures, and healthcare policy changes.-Fineline Info & Tech